NCT00635778 2018-10-09
MK-0646-002
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
10 trialsNCT01243762 2018-08-16
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00759785 2018-08-15
MK-0646-013
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00925015 2018-08-15
Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00694356 2018-08-08
Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00701103 2018-08-08
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01431547 2016-06-17
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00729742 2016-04-04
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00730379 2015-02-10
A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01220570 2015-01-21
The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)
Merck Sharp & Dohme LLC
Phase 1 Completed